PARIS - Sanofi (EPA:SASY) (NASDAQ:SNY)'s Board of Directors announced today that it will propose the appointment of Clotilde Delbos, Anne-Françoise Nesmes, and John Sundy as independent directors at the upcoming General Shareholder Meeting scheduled for April 30, 2024. This announcement comes as the healthcare company prepares for the departure of Diane Souza and Thomas Südhof from the board at the conclusion of their terms.
The proposed appointments aim to bolster the board's financial and scientific expertise, particularly in the field of immunology. Clotilde Delbos, with a background as Group CFO of Renault (EPA:RENA) and current director of Axa and Alstom (EPA:ALSO), brings extensive financial experience. Anne-Françoise Nesmes, set to step down as CFO of Smith + Nephew PLC, has a strong track record in finance roles across various international companies. John Sundy, currently Chief Medical Officer at Seicmic Therapeutic, offers significant scientific credentials with a focus on immunology.
The board will temporarily expand to 17 members to accommodate these changes and to prepare for the end of Fabienne Lecorvaisier's term as director and Chairman of the Audit Committee in 2025. The Chairman expressed gratitude to Souza and Südhof for their contributions and highlighted the board's ongoing commitment to diversity and the strategic development of the group.
Sanofi, a global healthcare leader, is dedicated to the pursuit of scientific innovations to enhance patient care across the world. The company's shares are traded on EURONEXT: SAN and NASDAQ: SNY.
This report is based on a press release statement from Sanofi.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.